 Steven Bair
Concepts (146)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hodgkin Disease | 8 | 2023 | 171 | 2.510 |
Why?
| | Immunotherapy, Adoptive | 6 | 2026 | 342 | 1.470 |
Why?
| | Antineoplastic Agents, Immunological | 4 | 2026 | 198 | 1.320 |
Why?
| | Immunoconjugates | 4 | 2025 | 138 | 0.920 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2020 | 699 | 0.830 |
Why?
| | Lymphoma | 1 | 2026 | 237 | 0.820 |
Why?
| | Precision Medicine | 2 | 2026 | 459 | 0.790 |
Why?
| | Medical Oncology | 1 | 2026 | 339 | 0.740 |
Why?
| | Computer Simulation | 1 | 2026 | 1003 | 0.670 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 4 | 2025 | 193 | 0.660 |
Why?
| | Machine Learning | 1 | 2026 | 587 | 0.610 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2019 | 76 | 0.550 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2019 | 161 | 0.540 |
Why?
| | Radiopharmaceuticals | 1 | 2019 | 205 | 0.540 |
Why?
| | Hematologic Neoplasms | 1 | 2020 | 168 | 0.520 |
Why?
| | Positron-Emission Tomography | 1 | 2019 | 343 | 0.510 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 265 | 0.490 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 261 | 0.480 |
Why?
| | Antineoplastic Agents | 2 | 2019 | 2214 | 0.430 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2020 | 1149 | 0.360 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 286 | 0.330 |
Why?
| | Angiogenesis Inhibitors | 1 | 2013 | 238 | 0.330 |
Why?
| | Iron Overload | 1 | 2008 | 19 | 0.290 |
Why?
| | Adoptive Transfer | 1 | 2008 | 200 | 0.280 |
Why?
| | Lymphoma, B-Cell | 2 | 2026 | 140 | 0.270 |
Why?
| | Iron | 1 | 2008 | 357 | 0.240 |
Why?
| | Antibodies, Bispecific | 1 | 2026 | 68 | 0.230 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 1963 | 0.220 |
Why?
| | Survival Rate | 3 | 2020 | 2090 | 0.220 |
Why?
| | Homeostasis | 1 | 2008 | 642 | 0.210 |
Why?
| | Transplantation, Homologous | 2 | 2020 | 418 | 0.200 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2024 | 20 | 0.200 |
Why?
| | Retrospective Studies | 11 | 2025 | 17291 | 0.190 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2023 | 134 | 0.180 |
Why?
| | Humans | 23 | 2026 | 145475 | 0.180 |
Why?
| | Treatment Outcome | 6 | 2026 | 11772 | 0.170 |
Why?
| | Prognosis | 4 | 2026 | 4316 | 0.160 |
Why?
| | Cardiovascular Diseases | 1 | 2013 | 2187 | 0.160 |
Why?
| | T-Lymphocytes | 1 | 2008 | 1996 | 0.160 |
Why?
| | Aged, 80 and over | 6 | 2026 | 8333 | 0.150 |
Why?
| | Recurrence | 2 | 2026 | 1138 | 0.150 |
Why?
| | Standard of Care | 1 | 2020 | 81 | 0.150 |
Why?
| | Disease-Free Survival | 2 | 2020 | 767 | 0.150 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2020 | 124 | 0.140 |
Why?
| | Transplantation Conditioning | 1 | 2020 | 191 | 0.140 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2025 | 992 | 0.140 |
Why?
| | Transplantation, Autologous | 1 | 2020 | 300 | 0.140 |
Why?
| | Costimulatory and Inhibitory T-Cell Receptors | 1 | 2018 | 7 | 0.140 |
Why?
| | Remission Induction | 1 | 2019 | 307 | 0.140 |
Why?
| | Aged | 8 | 2026 | 26153 | 0.130 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2025 | 881 | 0.130 |
Why?
| | Autografts | 1 | 2017 | 55 | 0.130 |
Why?
| | Immune Tolerance | 1 | 2019 | 385 | 0.120 |
Why?
| | Middle Aged | 8 | 2026 | 36215 | 0.110 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 484 | 0.110 |
Why?
| | Immunotherapy | 1 | 2020 | 666 | 0.110 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2014 | 23 | 0.110 |
Why?
| | Adult | 8 | 2026 | 40777 | 0.110 |
Why?
| | Transcription Factor RelA | 1 | 2014 | 86 | 0.100 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2013 | 28 | 0.100 |
Why?
| | Tumor Microenvironment | 1 | 2018 | 734 | 0.100 |
Why?
| | Gene Dosage | 1 | 2013 | 145 | 0.100 |
Why?
| | Cardiotoxins | 1 | 2013 | 3 | 0.100 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 1061 | 0.090 |
Why?
| | Vincristine | 2 | 2024 | 142 | 0.090 |
Why?
| | Cyclophosphamide | 2 | 2024 | 270 | 0.090 |
Why?
| | Medication Therapy Management | 1 | 2013 | 72 | 0.090 |
Why?
| | Prednisone | 2 | 2024 | 224 | 0.090 |
Why?
| | Rituximab | 2 | 2024 | 210 | 0.090 |
Why?
| | Carcinoma, Renal Cell | 1 | 2013 | 230 | 0.080 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2013 | 425 | 0.080 |
Why?
| | Male | 8 | 2026 | 72843 | 0.080 |
Why?
| | Atherosclerosis | 1 | 2014 | 409 | 0.080 |
Why?
| | Doxorubicin | 2 | 2024 | 401 | 0.080 |
Why?
| | Adolescent | 3 | 2020 | 22530 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2013 | 552 | 0.080 |
Why?
| | Female | 8 | 2026 | 78845 | 0.080 |
Why?
| | Nuclear Proteins | 1 | 2014 | 740 | 0.070 |
Why?
| | Kidney Neoplasms | 1 | 2013 | 413 | 0.070 |
Why?
| | Follow-Up Studies | 1 | 2018 | 5423 | 0.070 |
Why?
| | Apoproteins | 1 | 2008 | 15 | 0.070 |
Why?
| | Transferrin | 1 | 2008 | 50 | 0.070 |
Why?
| | Stromal Cells | 1 | 2008 | 121 | 0.070 |
Why?
| | Mice, SCID | 1 | 2008 | 369 | 0.070 |
Why?
| | Mice, Inbred NOD | 1 | 2008 | 613 | 0.060 |
Why?
| | Patient Care Team | 1 | 2013 | 696 | 0.060 |
Why?
| | Myelodysplastic Syndromes | 1 | 2008 | 165 | 0.060 |
Why?
| | Young Adult | 2 | 2024 | 14219 | 0.060 |
Why?
| | Transcription Factors | 1 | 2014 | 1734 | 0.060 |
Why?
| | Mice, Inbred BALB C | 1 | 2008 | 1261 | 0.060 |
Why?
| | Telomere | 1 | 2008 | 287 | 0.060 |
Why?
| | Etoposide | 1 | 2024 | 168 | 0.050 |
Why?
| | Benzodiazepines | 1 | 2025 | 168 | 0.050 |
Why?
| | Neoplasm, Residual | 1 | 2024 | 143 | 0.050 |
Why?
| | Antigens, CD19 | 1 | 2024 | 128 | 0.050 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2024 | 117 | 0.050 |
Why?
| | Inflammation | 1 | 2014 | 2878 | 0.050 |
Why?
| | Signal Transduction | 2 | 2014 | 5216 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2014 | 5983 | 0.040 |
Why?
| | Bleomycin | 1 | 2023 | 255 | 0.040 |
Why?
| | Time-to-Treatment | 1 | 2024 | 251 | 0.040 |
Why?
| | Ki-1 Antigen | 1 | 2021 | 7 | 0.040 |
Why?
| | Allografts | 1 | 2020 | 152 | 0.040 |
Why?
| | Canada | 1 | 2020 | 431 | 0.040 |
Why?
| | Mice | 3 | 2014 | 18329 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1891 | 0.030 |
Why?
| | Comorbidity | 1 | 2023 | 1661 | 0.030 |
Why?
| | Incidence | 1 | 2023 | 2923 | 0.030 |
Why?
| | SOXF Transcription Factors | 1 | 2014 | 16 | 0.030 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 42 | 0.030 |
Why?
| | Transcription Initiation, Genetic | 1 | 2014 | 19 | 0.030 |
Why?
| | E-Selectin | 1 | 2014 | 61 | 0.030 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2014 | 92 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2014 | 4148 | 0.030 |
Why?
| | Animals | 3 | 2014 | 38030 | 0.030 |
Why?
| | Sequestosome-1 Protein | 1 | 2013 | 15 | 0.030 |
Why?
| | Azepines | 1 | 2014 | 105 | 0.030 |
Why?
| | Acetylation | 1 | 2014 | 259 | 0.030 |
Why?
| | Enhancer Elements, Genetic | 1 | 2014 | 191 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2014 | 451 | 0.020 |
Why?
| | Triazoles | 1 | 2014 | 187 | 0.020 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2013 | 101 | 0.020 |
Why?
| | RNA Polymerase II | 1 | 2014 | 350 | 0.020 |
Why?
| | Chromatin | 1 | 2014 | 553 | 0.020 |
Why?
| | Base Sequence | 1 | 2013 | 2170 | 0.020 |
Why?
| | Cell Movement | 1 | 2014 | 959 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2014 | 1217 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 6013 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2013 | 2883 | 0.020 |
Why?
| | Histones | 1 | 2014 | 666 | 0.020 |
Why?
| | Protein Binding | 1 | 2014 | 2238 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2014 | 874 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1454 | 0.020 |
Why?
| | Quality of Life | 1 | 2020 | 3204 | 0.020 |
Why?
| | Endothelium, Vascular | 1 | 2014 | 956 | 0.020 |
Why?
| | Prospective Studies | 1 | 2020 | 8057 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2008 | 325 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2014 | 3124 | 0.020 |
Why?
| | Bone Marrow | 1 | 2008 | 306 | 0.020 |
Why?
| | United States | 1 | 2025 | 16098 | 0.020 |
Why?
| | Macrophages | 1 | 2014 | 1507 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 3542 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1041 | 0.010 |
Why?
| | Hematopoietic Stem Cells | 1 | 2008 | 435 | 0.010 |
Why?
| | Age Factors | 1 | 2008 | 3342 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2008 | 3623 | 0.010 |
Why?
|
|
Bair's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|